217 related articles for article (PubMed ID: 28450398)
1. Skeletal overgrowth-causing mutations mimic an allosterically activated conformation of guanylyl cyclase-B that is inhibited by 2,4,6,-trinitrophenyl ATP.
Dickey DM; Otto NM; Potter LR
J Biol Chem; 2017 Jun; 292(24):10220-10229. PubMed ID: 28450398
[TBL] [Abstract][Full Text] [Related]
2. A human skeletal overgrowth mutation increases maximal velocity and blocks desensitization of guanylyl cyclase-B.
Robinson JW; Dickey DM; Miura K; Michigami T; Ozono K; Potter LR
Bone; 2013 Oct; 56(2):375-82. PubMed ID: 23827346
[TBL] [Abstract][Full Text] [Related]
3. The pseudokinase domains of guanylyl cyclase-A and -B allosterically increase the affinity of their catalytic domains for substrate.
Edmund AB; Walseth TF; Levinson NM; Potter LR
Sci Signal; 2019 Jan; 12(566):. PubMed ID: 30696704
[TBL] [Abstract][Full Text] [Related]
4. An activating mutation in the kinase homology domain of the natriuretic peptide receptor-2 causes extremely tall stature without skeletal deformities.
Hannema SE; van Duyvenvoorde HA; Premsler T; Yang RB; Mueller TD; Gassner B; Oberwinkler H; Roelfsema F; Santen GW; Prickett T; Kant SG; Verkerk AJ; Uitterlinden AG; Espiner E; Ruivenkamp CA; Oostdijk W; Pereira AM; Losekoot M; Kuhn M; Wit JM
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1988-98. PubMed ID: 24057292
[TBL] [Abstract][Full Text] [Related]
5. The indolocarbazole, Gö6976, inhibits guanylyl cyclase-A and -B.
Robinson JW; Lou X; Potter LR
Br J Pharmacol; 2011 Sep; 164(2b):499-506. PubMed ID: 21366551
[TBL] [Abstract][Full Text] [Related]
6. Adenine nucleotides decrease the apparent Km of endogenous natriuretic peptide receptors for GTP.
Antos LK; Potter LR
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1756-63. PubMed ID: 17848634
[TBL] [Abstract][Full Text] [Related]
7. Guanylyl cyclases A and B are asymmetric dimers that are allosterically activated by ATP binding to the catalytic domain.
Robinson JW; Potter LR
Sci Signal; 2012 Sep; 5(240):ra65. PubMed ID: 22949736
[TBL] [Abstract][Full Text] [Related]
8. Stabilization of Perivascular Mast Cells by Endothelial CNP (C-Type Natriuretic Peptide).
Chen W; Werner F; Illerhaus A; Knopp T; Völker K; Potapenko T; Hofmann U; Frantz S; Baba HA; Rösch M; Zernecke A; Karbach S; Wenzel P; Kuhn M
Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):682-696. PubMed ID: 31893950
[TBL] [Abstract][Full Text] [Related]
9. Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases.
Potter LR
Pharmacol Ther; 2011 Apr; 130(1):71-82. PubMed ID: 21185863
[TBL] [Abstract][Full Text] [Related]
10. CREB activation in hypertrophic chondrocytes is involved in the skeletal overgrowth in epiphyseal chondrodysplasia Miura type caused by activating mutations of natriuretic peptide receptor B.
Yamamoto K; Kawai M; Yamazaki M; Tachikawa K; Kubota T; Ozono K; Michigami T
Hum Mol Genet; 2019 Apr; 28(7):1183-1198. PubMed ID: 30544148
[TBL] [Abstract][Full Text] [Related]
11. A constitutively "phosphorylated" guanylyl cyclase-linked atrial natriuretic peptide receptor mutant is resistant to desensitization.
Potter LR; Hunter T
Mol Biol Cell; 1999 Jun; 10(6):1811-20. PubMed ID: 10359598
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation-dependent regulation of the guanylyl cyclase-linked natriuretic peptide receptor B: dephosphorylation is a mechanism of desensitization.
Potter LR
Biochemistry; 1998 Feb; 37(8):2422-9. PubMed ID: 9485390
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of the major phosphorylation sites of the B-type natriuretic peptide receptor.
Potter LR; Hunter T
J Biol Chem; 1998 Jun; 273(25):15533-9. PubMed ID: 9624142
[TBL] [Abstract][Full Text] [Related]
14. Natriuretic Peptide Expression and Function in GH3 Somatolactotropes and Feline Somatotrope Pituitary Tumours.
Mirczuk SM; Scudder CJ; Read JE; Crossley VJ; Regan JT; Richardson KM; Simbi B; McArdle CA; Church DB; Fenn J; Kenny PJ; Volk HA; Wheeler-Jones CP; Korbonits M; Niessen SJ; McGonnell IM; Fowkes RC
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499110
[TBL] [Abstract][Full Text] [Related]
15. ATP potentiates competitive inhibition of guanylyl cyclase A and B by the staurosporine analog, Gö6976: reciprocal regulation of ATP and GTP binding.
Robinson JW; Potter LR
J Biol Chem; 2011 Sep; 286(39):33841-4. PubMed ID: 21828054
[TBL] [Abstract][Full Text] [Related]
16. The receptor attributable to C-type natriuretic peptide-induced differentiation of osteoblasts is switched from type B- to type C-natriuretic peptide receptor with aging.
Kaneki H; Kurokawa M; Ide H
J Cell Biochem; 2008 Feb; 103(3):753-64. PubMed ID: 17562543
[TBL] [Abstract][Full Text] [Related]
17. C-type natriuretic peptide regulation of guanosine-3',5'-cyclic monophosphate production in human endothelial cells.
Rautureau Y; Gowers I; Wheeler-Jones CP; Baxter GF
Auton Autacoid Pharmacol; 2010 Jul; 30(3):185-92. PubMed ID: 20085572
[TBL] [Abstract][Full Text] [Related]
18. Lysophosphatidic acid inhibits C-type natriuretic peptide activation of guanylyl cyclase-B.
Abbey SE; Potter LR
Endocrinology; 2003 Jan; 144(1):240-6. PubMed ID: 12488350
[TBL] [Abstract][Full Text] [Related]
19. cAMP inhibits natriuretic peptide receptor-B activity and increases C-type natriuretic peptide in FRTL-5 rat thyroid cells.
Sellitti DF; Puggina E; Lagranha C; Doi SQ
J Endocrinol; 2004 Jan; 180(1):23-34. PubMed ID: 14709141
[TBL] [Abstract][Full Text] [Related]
20. Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux.
Bartels CF; Bükülmez H; Padayatti P; Rhee DK; van Ravenswaaij-Arts C; Pauli RM; Mundlos S; Chitayat D; Shih LY; Al-Gazali LI; Kant S; Cole T; Morton J; Cormier-Daire V; Faivre L; Lees M; Kirk J; Mortier GR; Leroy J; Zabel B; Kim CA; Crow Y; Braverman NE; van den Akker F; Warman ML
Am J Hum Genet; 2004 Jul; 75(1):27-34. PubMed ID: 15146390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
